01 1Cipla
01 1VORTIOXETINE HYDROBROMIDE
01 1India
01 1Active
01 1Complete
GDUFA
DMF Review : Complete
Rev. Date : 2017-04-13
Pay. Date : 2017-02-23
DMF Number : 31389
Submission : 2017-03-04
Status : Active
Type : II
20
Cipla Ltd, based in India, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their notable products is VORTIOXETINE HYDROBROMIDE, with a corresponding US DMF Number 31389.
Remarkably, this DMF maintains an Active status since its submission on March 04, 2017, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of April 13, 2017, and payment made on February 23, 2017, indicating their dedication to facilitating drug approvals, Categorized as Type II
